| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology. |
From the Departments of Neurology (Dr. Foldvary-Schaefer) and Gynecology and Obstetrics (Dr. Falcone), The Cleveland Clinic Foundation, Cleveland, OH.
Address correspondence and reprint requests to Dr. Nancy Foldvary-Schaefer, The Cleveland Clinic Foundation, Department of Neurology, Section of Adult Epilepsy, 9500 Euclid Avenue, S-51, Cleveland, OH, 44195.
In women with epilepsy, seizures can be influenced by variations in sex hormone secretion during the menstrual cycle. The proconvulsant effects of estrogen have been demonstrated in both animals and humans, whereas progesterone has been found to have anticonvulsant properties. Catamenial epilepsy affects approximately one-third of women with epilepsy. This type of epilepsy has generally been defined as an increase in seizure frequency beginning immediately before or during menses. However, three distinct patterns of catamenial epilepsy have been described: perimenstrual, periovulatory, and luteal. The diagnosis of catamenial epilepsy can be made through careful assessment of menstrual and seizure diaries and characterization of cycle type and duration. A variety of therapies for catamenial epilepsy have been proposed, including acetazolamide, cyclical use of benzodiazepines or conventional antiepileptic drugs (AEDs), and hormonal therapy. However, evidence for the effectiveness of these treatment approaches comes from small, unblinded series or anecdotal reports. Larger multicenter trials, as well as further investigation of the pathophysiology of the disorder, are needed to identify the most effective treatment for women with catamenial epilepsy.
This article has been cited by other articles:
|
|
 |
|
  I. Colman, B. W Friedman, M. D Brown, G. D Innes, E. Grafstein, T. E Roberts, and B. H Rowe Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence BMJ, June 14, 2008; 336(7657): 1359 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Bigal, R. B. Lipton, P. R. Holland, and P. J. Goadsby Obesity, migraine, and chronic migraine: Possible mechanisms of interaction Neurology, May 22, 2007; 68(21): 1851 - 1861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Veliskova Estrogens and Epilepsy: Why Are We So Excited? Neuroscientist, February 1, 2007; 13(1): 77 - 88. [Abstract] [PDF]
|
|
|
|
 |
|
 L L. Mantia, D D'Amico, A Rigamonti, N Mascoli, G Bussone, and C Milanese Interferon treatment may trigger primary headaches in multiple sclerosis patients Multiple Sclerosis, August 1, 2006; 12(4): 476 - 480. [Abstract] [PDF]
|
|
|
|
|
|
M. E. Bigal and R. B. Lipton Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology, July 25, 2006; 67(2): 252 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Yokoyama, M Yoneda, M Abe, T Sakai, T Sagoh, Y Adachi, and T Kondo Internal carotid artery vasospasm syndrome: demonstration by neuroimaging J. Neurol. Neurosurg. Psychiatry, July 1, 2006; 77(7): 888 - 889. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jackson Epilepsy in women: a practical guide to management Practical Neurology, June 1, 2006; 6(3): 166 - 179. [Full Text] [PDF]
|
|
|
|
|
|
T. Hajszan and N. J. MacLusky Neurologic links between epilepsy and depression in women: Is hippocampal neuroplasticity the key? Neurology, March 28, 2006; 66(66_suppl_3): S13 - S22. [Abstract] [Full Text]
|
|
|
|
|
|
J. L. Brandes Treatment approaches to maximizing therapeutic response in migraine Neurology, October 28, 2003; 61(90084): S21 - 26. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
